Developer docs
API playgroundTry for free, no card

Search company profiles

Luxcel Biosciensces Ltd.

Full company profile

uuid003e9uc

Namestring
Luxcel Biosciensces Ltd.
Legal namestring
Luxcel Biosciensces Ltd.
Websiteurl
luxcel.com
Company typeenum
Public
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCork, Ireland
HQ citystring
Cork
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell metabolic analysis, live cell analysis, Seahorse XF technology, cellular bioenergetics, cell culture microplates
Industry2 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Measuring & Controlling Devices, Nec3829
Product category
Cell Analysis Instruments
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1XF Analyzers
TypeHardware Sales
Description

Sale of Seahorse XF analyzer instruments - capital equipment providing metabolic data on energy production in live cells in real time. Includes XF Pro analyzer with enhanced precision and pharma-oriented workflows.

agilent.com
2XF Sensor Cartridges & Cell Culture Microplates
TypeHardware Sales
Description

Recurring consumable revenue from proprietary sensor cartridges and specialized cell culture plates specific to application and cell type needs.

agilent.com
3XF Assay Kits, Reagents & Cell Assay Media
TypeHardware Sales
Description

Recurring consumable revenue from turnkey assay kits, reagents, and tested media for Seahorse XF workflows.

agilent.com
4XF Software Licenses & Support
TypeSubscription Recurring
Description

Software for assay design, data acquisition, analysis, and reporting with software upgrades and support services.

agilent.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Customers request quotes through Agilent's order center and account management system.

agilent.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Luxcel Biosciensces Ltd. is associated with the Seahorse XF real-time cell metabolic analysis platform, which provides noninvasive, real-time measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells via proprietary optical sensor cartridges and cell culture microplates. The offering spans XF analyzers (including the XF Pro), proprietary sensor cartridges and plates, turnkey assay kits/reagents/media, and XF software for assay design, data acquisition, and analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Seahorse XF Pro analyzer won 2023 Scientists' Choice Awards as best new drug discovery & development product of 2022
Product and service4 records
1Seahorse XF Analyzers (including XF Pro)
CategoryCell Analysis Instruments
Description

Capital equipment instrument that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells in real time, providing metabolic data on energy production. The XF Pro model adds enhanced precision and pharma-oriented workflows. For pharmaceutical, biopharma, and life science research customers.

2XF Sensor Cartridges & Cell Culture Microplates
CategoryConsumables
Description

Proprietary, application- and cell-type-specific consumables used with Seahorse XF analyzers to perform real-time metabolic measurements. Recurring consumable revenue stream. For pharmaceutical, biopharma, and research institution customers.

3XF Assay Kits, Reagents & Cell Assay Media
CategoryConsumables
Description

Ready-to-use, validated assay kits, reagents, and cell assay media that provide turnkey workflows for Seahorse XF metabolic assays. Recurring consumable revenue stream. For researchers using the Seahorse XF platform.

4XF Software Platform
CategorySoftware
Description

Software used to design XF assays, acquire data from the analyzer, and analyze and report cellular bioenergetics results. Includes upgrade and support services. For users of the Seahorse XF platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Analytical instruments specialist whose cell-analysis and molecular spectroscopy tools increasingly intersect with metabolic profiling workflows. Relevant as an emerging competitor in adjacent analytical categories.

TypeBroad incumbent
Description

Parent/incumbent that now commercializes the Seahorse XF / Luxcel-origin technology within its broader life-science instruments portfolio (mass spec, chromatography, cell analysis). Directly comparable as the operating channel for Luxcel's IP and the dominant commercial vehicle.

TypeBroad incumbent
Description

Life-science diagnostics and analytical instrument provider with overlapping cell-analysis, imaging, and lab-services capabilities serving pharma/biopharma research accounts.

TypeDirect peer
Description

Private life-science tools company supplying cell-based assay reagents, kits, and instruments. Comparable because its assay kits/reagents compete in similar pharma/biopharma cell-analysis workflows.

TypeDirect peer
Description

Direct peer in cell analysis and bioprocessing instrumentation serving pharma/biopharma with live-cell analysis and consumables. Closely aligned business model combining capital equipment with recurring consumables and overlapping drug-discovery workflows.

TypeDirect peer
Description

Developer of life-science research reagents, assay kits, and analytical instruments including cell-based assay workflows. Comparable due to overlapping assay kits/reagents revenue model and shared pharma/biopharma research customer base.

TypeOthers
Description

Global CDMO with cell-and-gene therapy manufacturing services. Comparable as a customer/channel partner for cell metabolism and potency assays used in therapeutic manufacturing QC.

TypeBroad incumbent
Description

Diversified life-sciences conglomerate with flow cytometry, cell analysis, and bioprocessing franchises that compete in adjacent instrument categories serving the same pharma/biopharma research customers.

TypeBroad incumbent
Description

Global life-science tools incumbent offering competing cell-analysis instruments, lab consumables, and pharma R&D workflows. Comparable because it sells overlapping capital equipment and consumables into the same pharmaceutical/biopharma customer base.

10Merck KGaA (Life Science / Sigma-Aldrich)
TypeBroad incumbent
Description

Broad life-science tools incumbent offering cell-culture media, reagents, and analytical instruments. Comparable due to overlapping consumables footprint and shared pharma/biopharma research customer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Luxcel Biosciensces Ltd.

Cell Analysis Instrumentsluxcel.com

Luxcel Biosciensces Ltd. firmographics

Firmographics
Name
Luxcel Biosciensces Ltd.
Legal name
Luxcel Biosciensces Ltd.
Website
https://luxcel.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Luxcel Biosciensces Ltd. industry classification

Industry
Product category
Cell Analysis Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Measuring & Controlling Devices, Nec (3829)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Cell metabolic analysis
  • Live cell analysis
  • Seahorse XF technology
  • Cellular bioenergetics
  • Cell culture microplates

Where Luxcel Biosciensces Ltd. is headquartered

Location

Headquarters

HQ city
Cork
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Luxcel Biosciensces Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. XF Analyzers: Sale of Seahorse XF analyzer instruments - capital equipment providing metabolic data on energy production in live cells in real time. Includes XF Pro analyzer with enhanced precision and pharma-oriented workflows.
  2. XF Sensor Cartridges & Cell Culture Microplates: Recurring consumable revenue from proprietary sensor cartridges and specialized cell culture plates specific to application and cell type needs.
  3. XF Assay Kits, Reagents & Cell Assay Media: Recurring consumable revenue from turnkey assay kits, reagents, and tested media for Seahorse XF workflows.
  4. XF Software Licenses & Support: Software for assay design, data acquisition, analysis, and reporting with software upgrades and support services.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Luxcel Biosciensces Ltd. product offering

Product offering

Core offering

Luxcel Biosciensces Ltd. is associated with the Seahorse XF real-time cell metabolic analysis platform, which provides noninvasive, real-time measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells via proprietary optical sensor cartridges and cell culture microplates. The offering spans XF analyzers (including the XF Pro), proprietary sensor cartridges and plates, turnkey assay kits/reagents/media, and XF software for assay design, data acquisition, and analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seahorse XF Analyzers (including XF Pro) Capital equipment instrument that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells in real time, providing metabolic data on energy production. The XF Pro model adds enhanced precision and pharma-oriented workflows. For pharmaceutical, biopharma, and life science research customers.
  • XF Sensor Cartridges & Cell Culture Microplates Proprietary, application- and cell-type-specific consumables used with Seahorse XF analyzers to perform real-time metabolic measurements. Recurring consumable revenue stream. For pharmaceutical, biopharma, and research institution customers.
  • XF Assay Kits, Reagents & Cell Assay Media Ready-to-use, validated assay kits, reagents, and cell assay media that provide turnkey workflows for Seahorse XF metabolic assays. Recurring consumable revenue stream. For researchers using the Seahorse XF platform.
  • XF Software Platform Software used to design XF assays, acquire data from the analyzer, and analyze and report cellular bioenergetics results. Includes upgrade and support services. For users of the Seahorse XF platform.

Quantifiable outcome

  • Seahorse XF Pro analyzer won 2023 Scientists' Choice Awards as best new drug discovery & development product of 2022

Companies that use Luxcel Biosciensces Ltd.

Customer profile

Segments4 records

Ideal customer profiles4 records

Luxcel Biosciensces Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Luxcel Biosciensces Ltd. partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights5 records

Luxcel Biosciensces Ltd. competitors and assessment

Company assessment

Emerging players

  • Bruker: Analytical instruments specialist whose cell-analysis and molecular spectroscopy tools increasingly intersect with metabolic profiling workflows. Relevant as an emerging competitor in adjacent analytical categories.

Broad incumbents

  • Agilent Technologies: Parent/incumbent that now commercializes the Seahorse XF / Luxcel-origin technology within its broader life-science instruments portfolio (mass spec, chromatography, cell analysis). Directly comparable as the operating channel for Luxcel's IP and the dominant commercial vehicle.
  • PerkinElmer: Life-science diagnostics and analytical instrument provider with overlapping cell-analysis, imaging, and lab-services capabilities serving pharma/biopharma research accounts.
  • Danaher (Beckman Coulter Life Sciences / Cytiva): Diversified life-sciences conglomerate with flow cytometry, cell analysis, and bioprocessing franchises that compete in adjacent instrument categories serving the same pharma/biopharma research customers.
  • Thermo Fisher Scientific: Global life-science tools incumbent offering competing cell-analysis instruments, lab consumables, and pharma R&D workflows. Comparable because it sells overlapping capital equipment and consumables into the same pharmaceutical/biopharma customer base.
  • Merck KGaA (Life Science / Sigma-Aldrich): Broad life-science tools incumbent offering cell-culture media, reagents, and analytical instruments. Comparable due to overlapping consumables footprint and shared pharma/biopharma research customer base.

Direct peers

  • Promega: Private life-science tools company supplying cell-based assay reagents, kits, and instruments. Comparable because its assay kits/reagents compete in similar pharma/biopharma cell-analysis workflows.
  • Sartorius: Direct peer in cell analysis and bioprocessing instrumentation serving pharma/biopharma with live-cell analysis and consumables. Closely aligned business model combining capital equipment with recurring consumables and overlapping drug-discovery workflows.
  • Bio-Techne: Developer of life-science research reagents, assay kits, and analytical instruments including cell-based assay workflows. Comparable due to overlapping assay kits/reagents revenue model and shared pharma/biopharma research customer base.

Others

  • Lonza: Global CDMO with cell-and-gene therapy manufacturing services. Comparable as a customer/channel partner for cell metabolism and potency assays used in therapeutic manufacturing QC.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Luxcel Biosciensces Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Luxcel Biosciensces Ltd. leadership team

Management profile

Number of profiles

Luxcel Biosciensces Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Luxcel Biosciensces Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luxcel Biosciensces Ltd.

What does Luxcel Biosciensces Ltd. do?

Luxcel Biosciensces Ltd. is associated with the Seahorse XF real-time cell metabolic analysis platform, which provides noninvasive, real-time measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells via proprietary optical sensor cartridges and cell culture microplates. The offering spans XF analyzers (including the XF Pro), proprietary sensor cartridges and plates, turnkey assay kits/reagents/media, and XF software for assay design, data acquisition, and analysis.

Is Luxcel Biosciensces Ltd. a public or private company?

Luxcel Biosciensces Ltd. is a public company. It is classified as unknown and is currently operating.

When was Luxcel Biosciensces Ltd. founded?

Luxcel Biosciensces Ltd. was founded in 2002. It employs 11 to 50 people.

Where is Luxcel Biosciensces Ltd. based?

Luxcel Biosciensces Ltd. is headquartered in Cork, Ireland, in the Europe region.

How does Luxcel Biosciensces Ltd. make money?

Four revenue lines are on record. XF Analyzers are the primary driver. The others are XF Sensor Cartridges & Cell Culture Microplates, XF Assay Kits, Reagents & Cell Assay Media and XF Software Licenses & Support.

Who are Luxcel Biosciensces Ltd.'s main competitors?

Bruker is listed as an emerging player. Broad incumbents are Agilent Technologies, PerkinElmer, Danaher (Beckman Coulter Life Sciences / Cytiva), Thermo Fisher Scientific and Merck KGaA (Life Science / Sigma-Aldrich). Direct peers are Promega, Sartorius and Bio-Techne. Lonza is listed as an others.

Does Luxcel Biosciensces Ltd. have an API?

No public API is recorded for Luxcel Biosciensces Ltd..

What industry is Luxcel Biosciensces Ltd. in?

Luxcel Biosciensces Ltd.'s product category is Cell Analysis Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLuxcel Biosciences Ltd Announces World First Physiologically Relevant, In Vitro Ischemia-Reperfusion Model in Conjunction with BMG LABTECH and NcardiaLuxcel Biosciences, BMG LABTECH, and Ncardia announced a first microplate-based in vitro ischemia-reperfusion model combining a CLARIOstar reader, MitoXpress oxygen assay, and iPSC-derived cardiomyocytes. The model enables real-time oxygenation monitoring to study IR injury and reduce reliance on animal models.PR NewswireLuxcel Biosciences Ltd Announces World First Physiologically Relevant, In Vitro Ischemia-Reperfusion Model in Conjunction with BMG LABTECH and NcardiaLuxcel Biosciences Ltd announced the development of the world's first microplate-based in vitro Ischemia-Reperfusion Model in partnership with BMG LABTECH GmbH and Ncardia, combining three technologies to better replicate and study IR injury biology. The model integrates BMG LABTECH's CLARIOstar microplate reader, Luxcel's MitoXpress Intra oxygen concentration assay, and Ncardia's iPSC-derived Cor.4U cardiomyocyte cells. This innovation is supported by the EU H2020 MetaCell-TM project and aims to reduce dependency on in vivo animal models while accelerating therapeutic drug discovery for conditions including cardiac arrest, stroke, and cancer.PR NewswireLuxcel Biosciences Ltd Announce Further EU H2020 Success with €1.5million Award and Rapid Expansion PlansLuxcel Biosciences Ltd announced a €1.5 million EU H2020 SME Instrument award to support MetaTox-HS product development, which includes their MitoXpress UHS and dOxyCheck in vitro test kits for cell metabolism and toxicity testing. The company's technology enables laboratory scientists to perform high-performance tests on standard fluorescence microplate readers already installed in approximately 20,000 labs worldwide, eliminating the need for new capital expenditure. The funding follows a €2.5 million H2020 Fast Track to Innovation award announced in February 2017 and underpins Luxcel's rapid expansion plans, with Pfizer cited as a key collaborator in drug safety and mitochondrial toxicity screening.PR NewswireLuxcel Biosciences Ltd, Axiogenesis AG and BMG LABTECH GmbH Secure €2.5m European Investment to Develop and Launch Cell Metabolism Analysis Platform: "MetaCell-TM"Luxcel Biosciences, Axiogenesis AG, and BMG LABTECH have secured €2.5 million in funding from the European Commission to develop and launch a cell metabolism analysis platform named MetaCell-TM. The project is part of the H2020 Fast Track to Innovation pilot and aims to provide a cost-effective alternative to expensive dedicated instrumentation for drug development research.